Antengene (HKG:6996) said Chinese regulators granted ATG-022 the breakthrough therapy designation, according to a Hong Kong bourse filing Tuesday.
Shares of the pharmaceutical company fell 4% in afternoon trade.
The designation covers ATG-022 as a treatment for a type of gastric cancer or gastroesophageal junction adenocarcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.